Durvalumab Plus TACE and Bevacizumab Significantly Improves PFS in Select HCC
Durvalumab plus concurrent transarterial chemoembolization followed by durvalumab with bevacizumab resulted in a significant improvement in PFS over TACE alone in patients with hepatocellular carcinoma who are eligible for embolization, meeting the primary end point of the phase 3 EMERALD-1 trial.
Source: onclive.com